Great Debates in Neovascular Retinal Disease: What Do the Data Really Tell Us About Treatment? is organized by Healio.
Release Date: 8/31/23
Expiration Date: 8/31/24
Program Overview:
With the recent availability of a first-ever bispecific antibody for neovascular retinal disease treatment, anti-vascular endothelial growth factor (VEGF) is not necessarily the most appropriate therapy for patients with age-related macular degeneration and diabetic macular edema. However, the data are complex and can be challenging to interpret. Join top retina experts as they debate and elucidate the finer points of recent clinical trials to guide pragmatic and evidence-based integration of novel therapy into retina practice.
Learning Objective:
Upon completion of this activity, participants should be able to:
• Identify differences between the clinical trial designs of novel therapy and anti-VEGF therapy, such as disease activity criteria for retreatment
• Describe key anatomic findings of clinical trial data comparing novel therapy with anti-VEGF therapy
• Summarize key findings of real-world studies from large registry databases related to the use of novel therapy
• Make treatment decisions for patients with neovascular retinal diseases (eg, switching and dosing intervals), based on data from clinical trials and real-world trials